Resistance of colorectal cancer cells to 5-FUdR and 5-FU caused by mycoplasma infection

Anticancer Research

Volumn 28, Issue 4 B, 2008, Pages 2175-2180

  Jetté, Lucie ^a   Bissoon Haqqani, Seema ^a,b   Le François, Brice ^a,b   Maroun, Jean A ^c   Birnboim, H Chaim ^a,b  

^a OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^b UNIVERSITY OF OTTAWA   (Canada)

^c OTTAWA REGIONAL CANCER CENTRE   (Canada)

Author keywords

5 FU; 5 FUdR; Mycoplasma; Resistance; Thymidylate synthase

Indexed keywords

ANTIBIOTIC AGENT; FLOXURIDINE; FLUOROURACIL; PLASMOCIN; THYMIDYLATE SYNTHASE;

ARTICLE; BACTERIAL INFECTION; BACTERIUM CONTAMINATION; CANCER CELL CULTURE; CANCER CELL DESTRUCTION; CANCER RESISTANCE; COLORECTAL CANCER; CONTROLLED STUDY; DRUG EFFICACY; DRUG SENSITIVITY; HUMAN; HUMAN CELL; IN VITRO STUDY; NONHUMAN; PRIORITY JOURNAL; WESTERN BLOTTING;

AMINOPTERIN; ANTIMETABOLITES, ANTINEOPLASTIC; COLORECTAL NEOPLASMS; DRUG RESISTANCE, NEOPLASM; FLOXURIDINE; FLUOROURACIL; HCT116 CELLS; HELA CELLS; HT29 CELLS; HUMANS; HYPOXANTHINE; MYCOPLASMA INFECTIONS; THYMIDINE; THYMIDINE KINASE; THYMIDYLATE SYNTHASE; TRITIUM;

EID: 49049115734     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Carreras CW and Santi DV: The catalytic mechanism and structure of thymidylate synthase. Annu Rev Biochem 64: 721-762,1995.
2. Danenberg PV: Thymidylate synthetase - a target enzyme in cancer chemotherapy. Biochim Biophys Acta 473: 73-92, 1977.
3. Hardy LW, Finer-Moore JS, Montfort WR, Jones MO, Santi DV and Stroud RM: Atomic structure of thymidylate synthase: target for rational drug design. Science 235: 448-455, 1987.
4. Santi DV, McHenry CS and Sommer H: Mechanism of interaction of thymidylate synthetase with 5-fluorodeoxy-uridylate. Biochemistry 13: 471-481, 1974.
5. Danenberg PV and Lockshin A: Fluorinated pyrimidines as tight-binding inhibitors of thymidylate synthetase. Pharmacol Ther 13: 69-90, 1981.
6. Berger SH, Jenh CH, Johnson LF and Berger FG: Thymidylate synthase overproduction and gene amplification in fluorodeoxyuridine-resistant human cells. Mol Pharmacol 28: 461-467, 1985.
7. Clark JL, Berger SH, Mittelman A and Berger FG: Thymidylate synthase gene amplification in a colon tumor resistant to fluoropyrimidine chemotherapy. Cancer Treat Rep 71: 261-265, 1987.
8. Copur S, Aiba K, Drake JC, Allegra CJ and Chu E: Thymidylate synthase gene amplification in human colon cancer cell lines resistant to 5-fluorouracil. Biochem Pharmacol 49: 1419-1426, 1995.
9. Johnston PG, Drake JC, Trepel J and Allegra CJ: Immunological quantitation of thymidylate synthase using the monoclonal antibody TS 106 in 5-fluorouracil-sensitive and -resistant human cancer cell lines. Cancer Res 52: 4306-4312, 1992.
10. Bapat AR, Zarow C and Danenberg PV: Human leukemic cells resistant to 5-fluoro-2'-deoxyuridine contain a thymidylate synthetase with lower affinity for nucleotides. J Biol Chem 258: 4130-4136,1983.
11. Berger SH, Barbour KW and Berger FG: A naturally occurring variation in thymidylate synthase structure is associated with a reduced response to 5-fluoro-2'-deoxyuridine in a human colon tumor cell line. Mol Pharmacol 34: 480-484, 1988.
12. Kawate H, Landis DM and Loeb LA: Distribution of mutations in human thymidylate synthase yielding resistance to 5-fluoro-deoxyuridine. J Biol Chem 277: 36304-36311, 2002.
13. Fernandes DJ and Cranford SK: Resistance of CCRF-CEM cloned sublines to 5-fluorodeoxyuridine associated with enhanced phosphatase activities. Biochem Pharmacol 34: 125-132,1985.
14. Zhang ZG, Harstrick A and Rustum YM: Mechanisms of resistance to fluoropyrimidines. Semin Oncol 19: 4-9, 1992.
15. Romanini A, Lin JT, Niedzwiecki D, Bunni M, Priest DG and Bertino JR: Role of folylpolyglutamates in biochemical modulation of fluoropyrimidines by leucovorin. Cancer Res 51: 789-793,1991.
16. Zhang ZG, Malmberg M, Yin MB, Slocum HK and Rustum YM: Isolation and characterization of a human ileocecal carcinoma cell line (HCT-8) subclone resistant to fluorodeoxyuridine. Biochem Pharmacol 45: 1157-1164, 1993.
17. Jastreboff MM and Zielinska ZM: Development and characteristics of a subline of Ehrlich ascites carcinoma cells persistently resistant to 5-fluoro-2'-deoxyuridine. Acta Biochim Pol 30: 185-191,1983.
18. Houghton PJ, Houghton JA, Germain G and Torrance PM: Development and characterization of a human colon adenocarcinoma xenograft deficient in thymidine salvage. Cancer Res 47: 2117-2122, 1987.
19. Sobrero AF, Moir RD, Bertino JR and Handschumacher RE: Defective facilitated diffusion of nucleosides, a primary mechanism of resistance to 5-fluoro-2'-deoxyuridine in the HCT-8 human carcinoma line. Cancer Res 45: 3155-3160, 1985.
20. Fry DW and Jackson RC: Membrane transport alterations as a mechanism of resistance to anticancer agents. Cancer Surv 5: 47-79, 1986.
21. Aronow B and Ullman B: Thymidine incorporation in nucleoside transport-deficient lymphoma cells. J Biol Chem 260: 16274-16278,1985.
22. Agarwal RP, Han T and Fernandez M: Reduced cellular transport and activation of fluoropyrimidine nucleosides and resistance in human lymphocytic cell lines selected for arabinosylcytosine resistance. Biochem Pharmacol 61: 39-47, 2001.
23. Lynch TP, Cass CE and Paterson AR: Defective transport of thymidine by cultured cells resistant to 5-bromodeoxyuridine. J Supramol Struct 6: 363-374, 1977.
24. Tezuka M, Sugiyama H, Tamemasa O and Inaba M: Biochemical characteristics of a 5-fluorouracil-resistant subline of P388 leukemia. Gann 73: 70-76, 1982.
25. Gray JH, Owen RP and Giacomini KM: The concentrative nucleoside transporter family, SLC28. Pflugers Arch 447: 728-734,2004.
26. Bunz F, Hwang PM, Torrance C, Waldman T, Zhang Y, Dillehay L, Williams J, Lengauer C, Kinzler KW and Vogelstein B: Disruption of p53 in human cancer cells alters the responses to therapeutic agents. J Clin Invest 104: 263-269, 1999.
27. Longley DB, Boyer J, Allen WL, Lauf T, Ferguson PR, Maxwell PJ, McDermott U, Lynch M, Harkin DP and Johnston PG: The role of thymidylate synthase induction in modulating p53-regulated gene expression in response to 5-fluorouracil and antifolates. Cancer Res 62: 2644-2649, 2002.
28. Giovannetti E, Backus HH, Wouters D, Ferreira CG, van Houten VM, Brakenhoff RH, Poupon MF, Azzarello A, Pinedo HM and Peters GJ: Changes in the status of p53 affect drug sensitivity to thymidylate synthase (TS) inhibitors by altering TS levels. Br J Cancer 96: 769-775, 2007.
29. Violette S, Poulain L, Dussaulx E, Pepin D, Faussat AM, Chambaz J, Lacorte JM, Staedel C and Lesuffleur T: Resistance of colon cancer cells to long-term 5-fluorouracil exposure is correlated to the relative level of Bcl-2 and BcI-X(L) in addition to Bax and p53 status. Int J Cancer 98: 498-504, 2002.
30. Carethers JM, Chauhan DP, Fink D, Nebel S, Bresalier RS, Howell SB and Boland CR: Mismatch repair proficiency and in vitro response to 5-fluorouracil. Gastroenterology 117: 123-131, 1999.
31. Meyers M, Wagner MW, Mazurek A, Schmutte C, Fishel R and Boothman DA: DNA mismatch repair-dependent response to fluoropyrimidine-generated damage. J Biol Chem 280: 5516-5526, 2005.
32. Meyers M, Hwang A, Wagner MW and Boothman DA: Role of DNA mismatch repair in apoptotic responses to therapeutic agents. Environ Mol Mutagen 44: 249-264, 2004.
33. Brattain MG, Levine AE, Chakrabarty S, Yeoman LC, Willson JK and Long B: Heterogeneity of human colon carcinoma. Cancer Metastasis Rev 3: 177-191, 1984.
34. Haqqani AS, Cowling RT, Maroun JA and Birnboim HC: Characterization of a polyclonal antibody to human thymidylate synthase suitable for the study of colorectal cancer specimens. J Histochem Cytochem 47: 1563-1574, 1999.
35. Merkenschlager M, Kardamakis D, Rawle FC, Spurr N and Beverley PC: Rate of incorporation of radiolabelled nucleosides does not necessarily reflect the metabolic state of cells in culture: effects of latent mycoplasma contamination. Immunology 63: 125-131, 1988.
36. Kawate H, Landis DM and Loeb LA: Distribution of mutations in human thymidylate synthase yielding resistance to 5-fluoro-deoxyuridine. J Biol Chem 277: 36304-36311, 2002.
37. Baldwin SA, Seal PR, Yao SY, King AE, Cass CE and Young JD: The equilibrative nucleoside transporter family, SLC29. Pflugers Arch 447: 735-743, 2004.
38. Arner ES and Eriksson S: Mammalian deoxyribonucleoside kinases. Pharmacol Ther 67: 155-186, 1995.
39. 3H]thyrnidine incorporation. J Immunol Methods 67: 337-345, 1984.
40. Hopert A, Uphoff CC, Wirth M, Hauser H and Drexler HG: Specificity and sensitivity of polymerase chain reaction (PCR) in comparison with other methods for the detection of mycoplasma contamination in cell lines. J Immunol Methods 164: 91-100,1993.